Revenue by segment/product/region: Subscription
Flow – sum over the period · $M
Q4 FY2025
1,315a$M
derived
All values (32)
| Period | Value ($M) | Status |
|---|---|---|
| Q4 FY2025 | 1,315 | derived |
| Q3 FY2025 | 1,234 | reported |
| Q2 FY2025 | 1,233 | reported |
| Q1 FY2025 | 1,192 | reported |
| Q4 FY2024 | 1,128 | derived |
| Q3 FY2024 | 1,046 | reported |
| Q2 FY2024 | 1,027 | reported |
| Q1 FY2024 | 988 | reported |
| Q4 FY2023 | 918 | derived |
| Q3 FY2023 | 838 | reported |
| Q2 FY2023 | 815 | reported |
| Q1 FY2023 | 764 | reported |
| Q4 FY2022 | 702 | derived |
| Q3 FY2022 | 640 | reported |
| Q2 FY2022 | 618 | reported |
| Q1 FY2022 | 579 | reported |
| Q4 FY2021 | 535 | derived |
| Q3 FY2021 | 474 | reported |
| Q2 FY2021 | 462 | reported |
| Q1 FY2021 | 428 | reported |
| Q4 FY2020 | 390 | derived |
| Q3 FY2020 | 354 | reported |
| Q2 FY2020 | 343 | reported |
| Q1 FY2020 | 319 | reported |
| Q4 FY2019 | 293 | derived |
| Q3 FY2019 | 259 | reported |
| Q2 FY2019 | 250 | reported |
| Q1 FY2019 | 231 | reported |
| Q4 FY2018 | 214 | derived |
| Q3 FY2018 | 192 | reported |
| Q2 FY2018 | 183 | reported |
| Q1 FY2018 | 169 | reported |
12 periods without value hidden · Show gaps with reason · CSV with all sources · Technical ID: seg_revenue / panw:SubscriptionMember
More metrics for Palo Alto Networks
Income statement
Balance sheet
Debt and interest
Sources & calculation
- Value
- $1.3B (derived)
- Period
- Q4 FY2025, ended Jul 31, 2025 · quarterly value (3 months, not cumulative)
- Calculation
- Q4 = fiscal year − 9 months cumulative = 4,974M − 3,659M = $1.3B (FY value from 10-K 0001327567-26-000023; 9-month value from the Q3-10-Q)
- Source
- 10-K, filed Sep 10, 2026 · 0001327567-26-000023
- Location
- us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax [srt:ProductOrServiceAxis=panw:SubscriptionMember]
- Confidence
- 1. – directly from an XBRL fact in the filing (or calculated exactly from it)
Versions
| v1 | $1.3B | Sep 10, 2026 | 10-K 0001327567-26-000023 | derived · confidence 1. · current |